Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members

Launched by GRAND HÔPITAL DE CHARLEROI · Mar 23, 2021

Keywords

ClinConnect Summary

Grand Hôpital de Charleroi (GHdC) staff were exposed to the risk of SARS-CoV-2 infection during the first half of 2020: a seroprevalence survey, conducted in the summer of 2020, after the "first wave" of the epidemic, and before the "second wave", thus revealed a significant seroprevalence because of its exposure. This study, because of its high participation rate, also showed the sustained interest of the agents in knowing their serology, either for personal reasons, or for the purposes of recognition as an occupational disease.

The GHdC decided in December 2020 to organize as soon as pos...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • To be an employee or independent collaborator at the GHdC
• Exclusion Criteria:
• • Refusal to take a blood test for anti-SARS-CoV-2 antibodies
• Regarding amendment 1:
• • Members who did not receive the third dose of PFIZER vaccine (Comirnaty) during the GHdC vaccination campaign and who did not performed a blood test to measure anti-SARS-CoV-2 antibodies.